In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.
In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.
Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.
Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132
As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.
Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.
Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.
Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132
Investments in Research Drives Market
Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.
The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.
This post was originally published on Food and Beverage Herald
See the original post here:
Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald
- BrightPath-Cellistic partner for clinical trial advancements of CAR-T cell therapy - Yahoo Finance - December 17th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 15th, 2024
- BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT... - December 13th, 2024
- Induced Pluripotent Stem Cells: Problems and Advantages when Applying ... - December 7th, 2024
- What are Induced Pluripotent Stem Cells? | ISCRM - December 7th, 2024
- Induced pluripotent stem cells, a giant leap for mankind therapeutic ... - December 7th, 2024
- Advantages and disadvantages of induced pluripotent stem cells - December 7th, 2024
- Generation and long-term culture of human cerebellar organoids from pluripotent stem cells - Nature.com - December 3rd, 2024
- Whats the secret to living to 100? Centenarian stem cells could offer clues - Nature.com - December 1st, 2024
- Single-cell RNA sequencing reveals key regulators and differentiation trajectory of iPSC-derived cardiomyocytes - Nature.com - November 26th, 2024
- Cell therapy weekly: GMP certification of iPSC-focused manufacturing facility - RegMedNet - November 25th, 2024
- Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - Pharmaceutical Technology - November 22nd, 2024
- Alloy Therapeutics, Takeda Partner on Revolutionary iPSC Cell Therapy Platform | TAK Stock News - StockTitan - November 22nd, 2024
- A remarkable study was released this week. It is a Japanese researcher's paper that restored vision - - November 18th, 2024
- World's first stem cell treatment restores vision, offers new hope to the blind - India Today - November 12th, 2024
- The Breakthroughs of Vision Restoration - The New Importance of Stem Cells - Yahoo News UK - November 12th, 2024
- Modified stem cell therapy aids motor function in mice with... - Parkinson's News Today - October 30th, 2024
- Team achieves successful reproduction of hematopoietic stem cell developmental process in an in vitro culture system - Phys.org - October 22nd, 2024
- Human Pluripotent Stem Cells (iPSC) Generation, Culture, and ... - October 11th, 2024
- Induced pluripotent stem cell technology: a decade of progress - October 11th, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 10th, 2024
- Human Induced Pluripotent Stem Cells : Clinical Significance and ... - October 6th, 2024
- Induced pluripotent stem cells: Mechanisms, achievements and ... - October 6th, 2024
- Induced pluripotent stem cells | UCLA BSCRC - October 6th, 2024
- Unlocking new regenerative pathways in iPS cellderived epicardium for cardiac repair - Medical Xpress - October 4th, 2024
- Artificial heart made of iPS cells unveiled to press, to be displayed at 2025 Osaka expo - The Mainichi - The Mainichi - October 2nd, 2024
- Trial planned on sparing diabetes patients from insulin injections - - September 30th, 2024
- Leveraging the power of iPS cell technology to study myeloid neoplasm - Medical Xpress - September 10th, 2024
- Kyoto University Hospital seeks to treat Type 1 diabetes using iPS cells - The Japan Times - September 4th, 2024
- Kyoto Hospital to Test Using Ips Cells to Treat Diabetes; Seeks to Reduce Burden of Multiple Daily Insulin Injections - The Japan News - September 4th, 2024
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - August 24th, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine - August 24th, 2024
- Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - August 24th, 2024
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 - August 24th, 2024
- Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow - August 24th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 24th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - August 24th, 2024
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - August 24th, 2024
- Novel insights from Human Induced Pluripotent Stem Cells on Origins and Roles of Fibro/Adipogenic Progenitors as Heterotopic Ossification Precursors -... - August 22nd, 2024
- Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity -... - August 18th, 2024
- Culture Techniques for Drug Discovery and Therapeutics - Technology Networks - August 16th, 2024
- iPSC culture techniques for drug discovery and therapeutics - Labmate Online - August 12th, 2024
- Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs - Frontiers - August 6th, 2024
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 31st, 2024
- Purification technologies for induced pluripotent stem cell therapies - Nature.com - July 28th, 2024
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results - July 26th, 2024
- Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research - July 26th, 2024
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - July 26th, 2024
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 - July 26th, 2024
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 - July 26th, 2024
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study - July 26th, 2024
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - July 26th, 2024
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 - July 26th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 - July 26th, 2024
- Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia - July 26th, 2024
- scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic... - July 26th, 2024
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 - July 26th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - July 26th, 2024
- Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - July 26th, 2024
- Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment... - July 26th, 2024
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health... - July 26th, 2024
- Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 - July 26th, 2024
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support - July 26th, 2024
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - July 26th, 2024
- ISSCR 2024: iPS cell line panels can be isogenic and diverse - BioWorld Online - July 16th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - PR Newswire - July 10th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - The Manila Times - July 10th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - July 5th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Monthly information on share capital and company voting rights - July 5th, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Integrating organoids and organ-on-a-chip devices - Nature.com - July 4th, 2024
- Very small embryonic-like stem cells have the potential to win the three-front war on tissue damage, cancer, and aging - Frontiers - July 2nd, 2024
- The progress of induced pluripotent stem cells derived from pigs: a mini review of recent advances - Frontiers - June 30th, 2024
- Regeneration of T cells from human-induced pluripotent stem cells for CAR-T cell medicated immunotherapy - Frontiers - June 30th, 2024
Recent Comments